决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.
基于自然杀伤(NK)细胞的免疫疗法在癌症治疗中具有前景,因为它们能够不依赖抗原呈递来清除癌细胞,并具备“现货型”实用性。
基于自然杀伤(NK)细胞的免疫疗法因其能够不依赖抗原呈递消除癌细胞以及“现货型”实用性,在癌症治疗中具有前景。然而,调控肿瘤对NK细胞毒性敏感性的分子决定因素仍不完全清楚。在此,我们采用CRISPR激活(CRISPRa)筛选来鉴定NK杀伤的癌细胞表面调控因子。使用聚焦表面蛋白组的文库,我们筛选了与NK细胞共培养的人和小鼠癌细胞系,鉴定了已知和新型调节NK细胞毒性的配体。筛选揭示了已确定的因子包括CD43以及先前未表征的调控因子CD44、PDPN和Siglec-1/CD169。通过正交方法验证,确认这些因子的破坏改变了体外和人性化小鼠模型中的NK杀伤敏感性。在机制上,我们发现CD43介导的NK抗性独立于其推测的与Siglec-7的相互作用,并且靶向NK细胞或CAR T细胞上的CD43显著增强了对白血病的细胞毒性活性。这些结果确立了功能获得性表面蛋白组筛选作为鉴定基于NK细胞免疫疗法治疗靶点的强大工具。
Natural killer (NK) cell-based immunotherapies are promising for cancer treatment due to their ability to eliminate cancer cells independently of antigen presentation and "off-the-shelf" utility. However, molecular determinants governing tumor susceptibility to NK cytotoxicity remain incompletely understood. Here we employ CRISPR activation (CRISPRa) screening to identify cancer cell surface regulators of NK killing. Using a surfaceome-focused library, we screen human and murine cancer cell lines co-cultured with NK cells, identifying known and novel ligands modulating NK cytotoxicity. Screens reveal established factors including CD43 and previously uncharacterized regulators CD44, PDPN, and Siglec-1/CD169. Validation with orthogonal approaches confirm that disruption of these factors alters NK killing susceptibility in vitro and in humanized mouse models. Mechanistically, we find that CD43-mediated NK resistance operates independently of its proposed interaction with Siglec-7, and that targeting CD43 on NK cells or CAR T cells substantially enhances cytotoxic activity against leukemia. These results establish gain-of-function surfaceome screening as a powerful tool for identifying therapeutic targets for NK cell-based immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。